Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian CancerSanghoon Lee, Anil K. Sood, Clifton L. Dalgard et al.|Cell Reports|2020Cited by 144
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Amir A. Jazaeri, Anne Knisely et al.|Nature|2025Cited by 30
Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapyDonastas Sakellariou-Thompson, Chantale Bernatchez, Marie-Andrée Forget et al.|Cancer Immunology Immunotherapy|2019Cited by 28
Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian CancerLi Zhao, Sanghoon Lee, Sara Corvigno et al.|Cancers|2022Cited by 10
Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers.Rodabe N. Amaria, Amir A. Jazaeri, Chantale Bernatchez et al.|Journal of Clinical Oncology|2019Cited by 6